发明名称 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
摘要 [Problem] To provide a compound having excellent platelet aggregation inhibitory activity. [Means for Resolution] It was found that quinolone derivatives characterized in that these have lower alkyl, cycloalkyl or the like at the 1-position; -N(R 0 )C(O)-lower alkylene-CO 2 R 0 , lower alkylene-CO 2 R 0 , lower alkenylene-CO 2 R 0 , -O-lower alkylene-CO 2 R 0 ,-O-(lower alkylene which may be substituted with -CO 2 R 0 )-aryl or -O-lower alkenylene-CO 2 R 0 (wherein R 0 is H or lower alkyl) at the 3-position; halogen at the 6-position; and amino group substituted with a substituent group having a ring structure at the 7-position, respectively, or pharmaceutically acceptable salts thereof, has excellent P2Y12 inhibitory activity. In addition, it was confirmed that these quinolone derivatives also have excellent platelet aggregation inhibitory activity. Based on the above, these quinolone derivatives or pharmaceutically acceptable salts thereof are useful as platelet aggregation inhibitors.
申请公布号 EP1995240(A1) 申请公布日期 2008.11.26
申请号 EP20070738511 申请日期 2007.03.14
申请人 ASTELLAS PHARMA INC. 发明人 KOGA, YUJI;OKUDA, TAKAO;WATANUKI, SUSUMU;KAMIKUBO, TAKASHI;HIRAYAMA, FUKUSHI;MORITOMO, HIROYUKI;FUJIYASU, JIRO;KAGEYAMA, MICHIHITO;UEMURA, TOSHIO;TAKASAKI, JUN
分类号 A61K31/519;C07D215/22;A61K31/47;A61K31/4709;A61K31/5377;A61K31/662;A61K31/683;A61K31/695;A61P7/02;A61P9/00;A61P9/04;C07D215/38;C07D237/28;C07D401/04;C07D401/06;C07D405/04;C07D405/12;C07D405/14;C07D409/14;C07D413/06;C07D413/12;C07D417/06;C07D417/12;C07D471/04 主分类号 A61K31/519
代理机构 代理人
主权项
地址